Development of Natural-Based Bone Cement for a Controlled Doxorubicin-Drug Release.
bone cement
nanoparticles
osteosarcoma
regenerative medicine
stem cells
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
03
2020
accepted:
12
06
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Osteosarcoma (OS) accounts for 60% of all global bone cancer diagnoses. Intravenous administration of Doxorubicin Hydrochloride (DOXO) is the current form of OS treatment, however, systemic delivery has been linked to the onset of DOXO induced cardiomyopathy. Biomaterials including calcium phosphate cements (CPCs) and nanoparticles (NPs) have been tested as localized drug delivery scaffolds for OS cells. However, the tumor microenvironment is critical in cancer progression, with mesenchymal stem cells (MSCs) thought to promote OS metastasis and drug resistance. The extent of MSC assisted survival of OS cells in response to DOXO delivered by CPCs is unknown. In this study, we aimed at investigating the effect of DOXO release from a new formulation of calcium phosphate-based bone cement on the viability of OS cells cocultured with hMSC in vitro. NPs made of PLGA were loaded with DOXO and incorporated in the formulated bone cement to achieve local drug release. The inclusion of PLGA-DOXO NPs into CPCs was also proven to increase the levels of cytotoxicity of U2OS cells in mono- and coculture after 24 and 72 h. Our results demonstrate that a more effective localized DOXO delivery can be achieved via the use of CPCs loaded with PLGA-DOXO NPs compared to CPCs loaded with DOXO, by an observed reduction in metabolic activity of U2OS cells in indirect coculture with hMSCs. The presence of hMSCs offer a degree of DOXO resistance in U2OS cells cultured on PLGA-DOXO NP bone cements. The consideration of the tumor microenvironment via the indirect inclusion of hMSCs in this study can act as a starting point for future direct coculture and
Identifiants
pubmed: 32733869
doi: 10.3389/fbioe.2020.00754
pmc: PMC7363953
doi:
Types de publication
Journal Article
Langues
eng
Pagination
754Informations de copyright
Copyright © 2020 Dewhurst, Scalzone, Buckley, Mattu, Rankin, Gentile and Ferreira.
Références
J Biomed Mater Res B Appl Biomater. 2019 May;107(4):1150-1158
pubmed: 30281905
Biomaterials. 2011 Dec;32(34):8839-47
pubmed: 21871661
Acta Biomater. 2008 Nov;4(6):1837-45
pubmed: 18555756
Biomaterials. 2009 Oct;30(30):6094-101
pubmed: 19674782
Tissue Eng Part A. 2016 May;22(9-10):788-800
pubmed: 27083055
J Mater Sci Mater Med. 2011 Dec;22(12):2659-72
pubmed: 22002512
Ir J Med Sci. 2015 Mar;184(1):101-6
pubmed: 25428698
J Biomed Mater Res A. 2014 Dec;102(12):4394-405
pubmed: 24522948
Stem Cell Res Ther. 2018 Jan 31;9(1):22
pubmed: 29386041
Biomaterials. 2011 Aug;32(23):5411-6
pubmed: 21529931
Adv Drug Deliv Rev. 2010 Mar 8;62(3):346-61
pubmed: 19914317
J Surg Oncol. 2006 Mar 1;93(3):212-20
pubmed: 16482601
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109863
pubmed: 31349467
Cell Mol Life Sci. 2019 Feb;76(3):609-625
pubmed: 30430199
Biomed Pharmacother. 2017 Nov;95:1209-1218
pubmed: 28931213
Biomaterials. 1999 Feb;20(4):393-8
pubmed: 10048413
Biomacromolecules. 2005 Mar-Apr;6(2):975-87
pubmed: 15762668
J Photochem Photobiol B. 2018 Aug;185:100-110
pubmed: 29885646
Pediatr Blood Cancer. 2017 Jun;64(6):
pubmed: 27860191
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:249-257
pubmed: 26652371
J Appl Biomater Funct Mater. 2019 Oct-Dec;17(4):2280800019872594
pubmed: 31718388
Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110460
pubmed: 31923975
Acta Biomater. 2018 Oct 15;80:341-351
pubmed: 30236799
Acta Biomater. 2014 Mar;10(3):1035-49
pubmed: 24231047
Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70
pubmed: 22339066
J Mater Sci Mater Med. 2008 Jun;19(6):2485-92
pubmed: 18253814
J Bone Miner Res. 2010 Apr;25(4):683-91
pubmed: 20205169
J Hematol Oncol. 2014 Feb 06;7:14
pubmed: 24502410
Int J Cancer. 2012 Aug 15;131(4):E508-17
pubmed: 21913189
J Clin Oncol. 2013 Jun 20;31(18):2303-12
pubmed: 23669227
J Biomed Mater Res A. 2019 Aug;107(8):1713-1722
pubmed: 30920119
Int J Pharm. 2020 Apr 30;580:119246
pubmed: 32205141
Expert Rev Anticancer Ther. 2018 Jan;18(1):39-50
pubmed: 29210294
J Mater Sci Mater Med. 2018 Sep 4;29(9):149
pubmed: 30182158
DNA Cell Biol. 2007 Jan;26(1):1-18
pubmed: 17263592
Exp Cell Res. 2014 Jan 1;320(1):164-73
pubmed: 24183998
J Gastrointest Oncol. 2017 Feb;8(1):E26-E30
pubmed: 28280633
Int J Biol Macromol. 2018 Apr 15;110:97-109
pubmed: 28866015
Nanomedicine (Lond). 2007 Dec;2(6):899-918
pubmed: 18095853
Adv Drug Deliv Rev. 2007 May 30;59(4-5):234-48
pubmed: 17478007
Int J Biol Macromol. 2016 Dec;93(Pt B):1354-1365
pubmed: 26845481
J Biomed Mater Res A. 2008 Aug;86(2):311-22
pubmed: 17969018
Clin Oral Investig. 2014 Jul;18(6):1597-604
pubmed: 24233183
J Orthop Sci. 2011 Jan;16(1):77-84
pubmed: 21360005
ACS Appl Mater Interfaces. 2015 Dec 16;7(49):27040-8
pubmed: 26575336
Bioact Mater. 2020 Feb 12;5(1):164-183
pubmed: 32083230
Acta Biomater. 2011 Apr;7(4):1752-9
pubmed: 21185953
J Biomed Mater Res A. 2007 Feb;80(2):351-61
pubmed: 17001653
Nanoscale. 2016 Aug 14;8(30):14411-9
pubmed: 27411852
J Biomater Appl. 2016 Jan;30(6):838-45
pubmed: 26329353
Biomaterials. 2004 May;25(11):2197-203
pubmed: 14741635
Semin Cancer Biol. 2014 Apr;25:33-46
pubmed: 24406210
Trends Biotechnol. 2010 Nov;28(11):580-8
pubmed: 20724010
Medicine (Baltimore). 2019 May;98(19):e15582
pubmed: 31083238
Dent Mater. 2007 Apr;23(4):433-41
pubmed: 16678895
Acta Biomater. 2009 Sep;5(7):2752-62
pubmed: 19357005
Dent Mater J. 2016;35(2):216-24
pubmed: 27041011
J Biomed Mater Res A. 2003 Feb 1;64(2):262-72
pubmed: 12522813
Tex Heart Inst J. 2012;39(3):424-7
pubmed: 22719160
Bone Res. 2017 Dec 20;5:17056
pubmed: 29354304
Sci Rep. 2019 Feb 14;9(1):2002
pubmed: 30765730
J Mater Sci Mater Med. 2016 May;27(5):89
pubmed: 26975746
Anticancer Drugs. 2005 Jul;16(6):667-74
pubmed: 15930896
J Bone Joint Surg Am. 1998 Aug;80(8):1112-24
pubmed: 9730120
Pediatr Blood Cancer. 2012 Mar;58(3):327-33
pubmed: 21990244
Onco Targets Ther. 2016 Nov 22;9:7207-7218
pubmed: 27920558
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
Biomaterials. 2005 Apr;26(12):1337-48
pubmed: 15482821
Int J Hematol. 2018 Mar;107(3):286-296
pubmed: 29022209